Effect of Epidural Hydromorphone Combined With Ropivacaine in Labor Analgesia
NCT ID: NCT05901441
Last Updated: 2023-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
240 participants
INTERVENTIONAL
2022-06-01
2023-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be randomly allocated to four groups: H1 group,H2 group,H3 group and SF group.For those in H1 group: they will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H3 group: they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in SF group: they will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine for epidural labor analgesia.
The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Sufentanil and Ropivacaine
NCT02488291
Dexmedetomidine-Ropivacine Versus Sufentanil-Ropivacaine for Epidural Labor Analgesia
NCT05698407
Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil
NCT03622047
Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia
NCT07145775
Onset of Labour Epidural Analgesia With Different Concentration Bupivacaine and Different Doses of Sufentanyl
NCT03395600
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
H1 group
H1 group will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine
Hydromorphone
For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
Ropivacaine
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
H2 group
H2 group will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine
Hydromorphone
For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
Ropivacaine
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
H3 group
H3 group will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine
Hydromorphone
For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
Ropivacaine
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
SF group
SF group will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine
Sufentanil
For those in SF group: they will be administered with 40 ug/ml sufentanil
Ropivacaine
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydromorphone
For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
Sufentanil
For those in SF group: they will be administered with 40 ug/ml sufentanil
Ropivacaine
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maternal and Child Health Hospital of Hubei Province
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Na
Deputy Chief Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Na Li, MD
Role: PRINCIPAL_INVESTIGATOR
Maternal and Child Health Hospital of Hubei Province
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maternal and Child Health Hospital of Hubei Province
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCHH_002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.